Cargando…

Efficacy and safety of zolbetuximab for first-line treatment of advanced Claudin 18. 2-positive gastric or gastro-esophageal junction adenocarcinoma: a systematic review and meta-analysis of randomized controlled trials

OBJECTIVE: Zolbetuximab is a “first-in-class” chimeric lgG1 monoclonal antibody targeting Claudin18.2 (CLDN 18.2). In recent years, several important trials have been published showing that zolbetuximab is associated with improved prognosis in patients with advanced gastric or gastro-esophageal junc...

Descripción completa

Detalles Bibliográficos
Autores principales:	Liang, Zhanpeng, Liu, Liwen, Li, Wenxia, Lai, Huiqin, Li, Luzhen, Wu, Jiaming, Zhang, Huatang, Fang, Cantu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10598679/ https://www.ncbi.nlm.nih.gov/pubmed/37886169 http://dx.doi.org/10.3389/fonc.2023.1258347

Ejemplares similares

Claudin 18.2 is a potential therapeutic target for zolbetuximab in pancreatic ductal adenocarcinoma
por: Wang, Xi, et al.
Publicado: (2022)

ILUSTRO: Phase II Multicohort Trial of Zolbetuximab in Patients with Advanced or Metastatic Claudin 18.2–Positive Gastric or Gastroesophageal Junction Adenocarcinoma
por: Klempner, Samuel J., et al.
Publicado: (2023)

Efficacy and safety of salvage radiotherapy combined with endocrine therapy in patients with biochemical recurrence after radical prostatectomy: A systematic review and meta-analysis of randomized controlled trials
por: Liang, Zhanpeng, et al.
Publicado: (2023)

Phase 1 trial of zolbetuximab in Japanese patients with CLDN18.2+ gastric or gastroesophageal junction adenocarcinoma
por: Shitara, Kohei, et al.
Publicado: (2022)

Zolbetuximab plus CAPOX in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: the randomized, phase 3 GLOW trial
por: Shah, Manish A., et al.
Publicado: (2023)

Successes and failures of angiogenesis blockade in gastric and gastro-esophageal junction adenocarcinoma
por: Salati, Massimiliano, et al.
Publicado: (2022)

Prognostic impact of Claudin 18.2 in gastric and esophageal adenocarcinomas
por: Arnold, A., et al.
Publicado: (2020)

Spontaneous Regression of Metastatic Lesions of Adenocarcinoma of the Gastro-Esophageal Junction
por: Mitchell, Richard, et al.
Publicado: (2021)

Characterization of zolbetuximab in pancreatic cancer models
por: Türeci, Ӧzlem, et al.
Publicado: (2018)

Clinical role of ramucirumab alone or in combination with paclitaxel for gastric and gastro-esophageal junction adenocarcinoma
por: Davidson, Michael, et al.
Publicado: (2016)

Case report: pathological complete response in an IIIB non-small cell lung cancer patient after preoperative neoadjuvant nivolumab therapy combined with chemotherapy
por: Li, Luzhen, et al.
Publicado: (2022)

A single-center randomized controlled study of intraperitoneal hyperthermic chemoperfusion in combination of recombinant human tumor necrosis factor (TNF) in treatment of malignant ascites caused by advanced abdominal cancers
por: Wu, Lexia, et al.
Publicado: (2022)

Prognostic value of claudin 18.2 expression in gastric adenocarcinoma
por: Kayikcioglu, Erkan, et al.
Publicado: (2023)

Claudin 18.2 expression in esophageal adenocarcinoma and its potential impact on future treatment strategies
por: Moentenich, Valeska, et al.
Publicado: (2020)

Claudin18.who? Examining biomarker overlap and outcomes in claudin18.2-positive gastroesophageal adenocarcinomas
por: Klempner, S.J., et al.
Publicado: (2023)

Enduring complete metabolic response in metastatic adenocarcinoma of the gastro-oesophageal junction
por: Li, Minmin, et al.
Publicado: (2014)

Ascending colon cecal junction carcinoma with prostate metastasis: A case report and literature review
por: Zhu, Wanshan, et al.
Publicado: (2023)

S-1 plus cisplatin versus fluorouracil plus cisplatin in advanced gastric or gastro-esophageal junction adenocarcinoma patients: a pilot study
por: Li, Yuhong, et al.
Publicado: (2015)

Cost-effectiveness analysis of zolbetuximab plus mFOLFOX6 as the first-line treatment for CLDN18.2-positive, HER2-negative advanced gastric or Gastroesophageal Adenocarcinoma
por: Huang, Yufan, et al.
Publicado: (2023)

Minimum biopsy set for HER2 evaluation in gastric and gastro-esophageal junction cancer
por: Gullo, Irene, et al.
Publicado: (2015)

The tight junction protein claudin 6 is a potential target for patient-individualized treatment in esophageal and gastric adenocarcinoma and is associated with poor prognosis
por: Simon, Adrian Georg, et al.
Publicado: (2023)

Epidermal Growth Factor (EGFR) copy number aberrations in esophageal and gastro-esophageal junctional carcinoma
por: Dahle-Smith, Åsa, et al.
Publicado: (2015)

Significance of tumour regression in lymph node metastases of gastric and gastro‐oesophageal junction adenocarcinomas
por: Reim, Daniel, et al.
Publicado: (2020)

Systemic chemotherapy for gastro-oesophagogastric junction adenocarcinoma and stomach adenocarcinoma in a metastatic setting
por: Sanjeevaiah, Aravind, et al.
Publicado: (2020)

Nutritional index for immune-checkpoint inhibitor in patients with metastatic gastro-esophageal junction/gastric cancer
por: Morelli, Cristina, et al.
Publicado: (2022)

Widespread choriocarcinoma metastases from de-differentiated gastro-esophageal junction primary adenocarcinoma: A case report with literature review
por: Schrader, Evan, et al.
Publicado: (2019)

Phase II study of TP300 in patients with advanced gastric or gastro-oesophageal junction adenocarcinoma
por: Propper, David, et al.
Publicado: (2016)

Immunological effects and activity of multiple doses of zolbetuximab in combination with zoledronic acid and interleukin-2 in a phase 1 study in patients with advanced gastric and gastroesophageal junction cancer
por: Lordick, Florian, et al.
Publicado: (2023)

The relevance of the Siewert classification in the era of multimodal therapy for adenocarcinoma of the gastro-oesophageal junction
por: Curtis, Nathan J, et al.
Publicado: (2014)

The Evolution of Neo-Adjuvant Therapy in the Treatment of Oesophageal and Gastro-Oesophageal Junction Adenocarcinomas
por: Dermanis, Alexander A., et al.
Publicado: (2023)

Immunoexpression of Claudin 4 in Gastric Adenocarcinomas
por: CREȚU, OANA IULIA, et al.
Publicado: (2022)

Machine Learning for Future Subtyping of the Tumor Microenvironment of Gastro-Esophageal Adenocarcinomas
por: Klein, Sebastian, et al.
Publicado: (2021)

Claudin-18 Loss Alters Transcellular Chloride Flux but not Tight Junction Ion Selectivity in Gastric Epithelial Cells
por: Caron, Tyler J., et al.
Publicado: (2020)

Comprehensive clinical and molecular characterization of claudin 18.2 expression in advanced gastric or gastroesophageal junction cancer
por: Kubota, Y., et al.
Publicado: (2023)

Economic evaluation of FLOT and ECF/ECX perioperative chemotherapy in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma
por: Zeng, Hanqing, et al.
Publicado: (2022)

Claudin interactions in and out of the tight junction
por: Van Itallie, Christina M, et al.
Publicado: (2013)

Patient-reported outcomes from the phase II FAST trial of zolbetuximab plus EOX compared to EOX alone as first-line treatment of patients with metastatic CLDN18.2+ gastroesophageal adenocarcinoma
por: Lordick, Florian, et al.
Publicado: (2021)

Adenocarcinoma of oesophagus involving gastro-oesophageal junction following mini-gastric bypass/ one anastomosis gastric bypass
por: Aggarwal, Sandeep, et al.
Publicado: (2020)

Minimally invasive surgery for gastro-oesophageal junction adenocarcinoma: Current evidence and future perspectives
por: Bîrlă, Rodica, et al.
Publicado: (2023)

Prognostic value of pre-therapeutic FDG-PET radiomic analysis in gastro-esophageal junction cancer
por: Amrane, Karim, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_dcuhfoq57406k1ft8jl91co28q